Atherosclerotic Cardiovascular Disease - Epidemiology Forecast - 2036

ASCVD Insights and Trends

• ASCVD prevalence continues to rise across the 7MM due to population aging, improved post-event survival, and sustained exposure to cardiometabolic risk factors, expanding the long-term secondary prevention pool.
• The burden of ASCVD increases sharply with age. Prevalence is significantly higher in older adults, particularly among medically insured populations, where comorbidity levels and cardiovascular risk factors accumulate. Younger commercial populations, though affected, display comparatively lower disease severity.
• PAD constitutes the largest share of ASCVD cases across all payer and demographic groups. Stroke, including ischemic stroke, is the second most common subtype, followed by coronary revascularization and recent ACS, underscoring the multi-system impact of atherosclerosis.
• The consistent male predominance and earlier onset of ASCVD underscores the need for targeted gender-specific screening and early intervention strategies, particularly before hormonal protection in women diminishes.
• In the 7MM, the United States recorded the highest number of diagnosed prevalent ASCVD cases in 2025, with this burden expected to continue increasing through 2036. Emerging analyses from large claims databases indicate a notable uptick in diagnoses, reflecting growing awareness and better detection of the disease.
• Among the EU4 and the UK, Germany accounted for the highest number of ASCVD cases, followed by Italy and France, whereas Spain accounted for the lowest number of cases in 2025.
• Concentration of cases in older adults indicates cumulative risk and delayed diagnosis, emphasizing opportunities for earlier risk stratification and preventive measures across middle-aged populations.

ASCVD Epidemiology forecast (7MM)

• 2025 ASCVD Patient pool: ~65,415,200
• 2036 Projected ASCVD Patient pool: ~76,081,000
• ASCVD Growth Rate (2026-2036): 1.4% CAGR

DelveInsight's 'Atherosclerotic Cardiovascular Disease (ASCVD)- Epidemiology Forecast - 2036' report delivers an in-depth understanding of the ASCVD, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

ASCVD Understanding

ASCVD Overview and Diagnosis

ASCVD is a medical condition characterized by the buildup of fatty deposits (plaques) on the inner walls of arteries. These plaques consist of cholesterol, fatty substances, calcium, and other cellular waste products. Over time, the plaques can harden and narrow the arteries, which reduces blood flow to vital organs and tissues. It is a progressive and chronic condition that can affect various arteries throughout the body, including those supplying the heart (coronary arteries), brain (cerebral arteries), and legs (peripheral arteries). The most common manifestations of ASCVD include Coronary Artery Disease (CAD), cerebrovascular disease (stroke), and Peripheral Arterial Disease (PAD).

ASCVD Diagnosis

Diagnosis of ASCVD is based on a combination of clinical evaluation, laboratory tests, genetic analysis, and imaging techniques. Initial assessment typically includes lipid profile testing measuring total cholesterol, LDL-C, HDL-C, and triglycerides along with additional biomarkers such as apolipoproteins, hsCRP, and lipoprotein (a) in selected patients to refine cardiovascular risk. Genetic testing may be used in individuals with suspected familial hypercholesterolemia by evaluating genes such as LDLR, APOB, PCSK9, or LDLRAP1. Imaging methods including ultrasonography, CT, MRI/MRA, and invasive catheter angiography help detect arterial plaques, stenosis, or calcification, while electrocardiography can identify reduced blood flow to the heart. Regular lipid monitoring is recommended to evaluate treatment response and guide risk-based lipid management.

ASCVD Epidemiology

Key Findings from ASCVD Epidemiological Analysis and Forecast

• As per the estimates by DelveInsight, the total diagnosed prevalent cases of ASCVD in the 7MM was 65,415,000 in 2025.
• In 2025, approximately 55% of ASCVD cases in the US occurred in males and 45% in females, accounting for around 17,300,000 male cases and 13,800,000 female cases.
• Different age groups are counted for DelveInsight's epidemiology model; ASCVD is categorized into age groups 18-44 years, 45-64 years, and 65 years and above. Among these age groups, the 65 and above age group was estimated to have the highest number of diagnosed ASCVD cases in EU4 and the UK in 2025. The number of diagnosed cases for 65+ age groups was approximately 15,900,000; however, it should be noted that the least number of cases were found in patients aged 18-44 years in 2025.
• As per DelveInsight's analysis, the comorbidity-specific diagnosed prevalent cases of ASCVD in Japan in 2025 were highest for Peripheral Artery Disease (PAD) at approximately 1,936,000 cases, while the lowest prevalence was observed in Acute Coronary Syndrome (ACS) with about 102,000 cases.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of ASCVD, explaining its causes, signs and symptoms, pathogenesis, and Patient burden.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
• A detailed review of the ASCVD epidemiology, detailed assumptions, and rationale behind the approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Report Insights

• ASCVD patient population forecast
• Country-wise epidemiology distribution

Report Key Strengths

• Epidemiology-based (Epi-based) bottom-up forecasting
• 11-year forecast
• Patient Burden trends (by geography)

Report Assessment

• Epidemiology Segmentation
• Current Diagnostic practices

FAQs:

Market Insights

• What are the patient burden trends of ASCVD in the seven major markets?
• What are the disease risk, burden, and unmet needs of ASCVD? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to ASCVD?
• What is the historical ASCVD patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of ASCVD at the 7MM level?
• Out of the countries mentioned above, which country would have the highest prevalence of ASCVD during the study period (2022-2036)?
• At what CAGR is the population expected to grow across the 7MM during the study period (2022-2036)?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the ASCVD market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.